Application of Yttrium-90 microsphere selective internal radiation therapy in downstaging and conversion of hepatocellular carcinoma: a case report
10.12025/j.issn.1008-6358.2025.20250023
- VernacularTitle:钇-90微球选择性内放射治疗在肝细胞癌降期转化中的应用1例报告
- Author:
Ziwei LIANG
1
,
2
;
Tiantian ZHANG
1
,
2
;
Yong LIAO
3
,
4
;
Xin HUANG
3
,
4
;
Bin LIANG
3
,
5
;
Zhongbin HANG
1
,
6
;
Yan ZHANG
7
;
Lin ZHANG
3
,
4
;
Xiaobin FENG
3
,
4
;
Li HUO
8
Author Information
1. Department of Nuclear Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China
2. Yttrium-90 Precision Interventional Radiotherapy Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.
3. Yttrium-90 Precision Interventional Radiotherapy Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China
4. Department of Hepatobiliary and Pancreatic Surgery, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.
5. Department of Radiology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.
6. School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
7. Department of Nuclear Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China.
8. Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China.
- Publication Type:Monographicreport:Yttrium-90microsphereinternalradiationtherapyonlivercancer
- Keywords:
hepatocellular carcinoma;
Yttrium-90;
downstaging;
conversion
- From:
Chinese Journal of Clinical Medicine
2025;32(1):41-45
- CountryChina
- Language:Chinese
-
Abstract:
This case report describes a 68-year-old male patient diagnosed with primary hepatocellular carcinoma (HCC). After receiving Yttrium-90 microsphere selective internal radiation therapy (90Y-SIRT), the tumor significantly reduced in size, and tumor markers alpha fetoprotein (AFP) and abnormal prothrombin (PIVKA-Ⅱ) decreased. Postoperative pathological results showed minimal residual tumor cells, indicating that 90Y-SIRT has good efficacy and safety in downstaging and conversion of HCC, thereby facilitating subsequent surgical resection.
